Nasdaq

Teva presents Phase 3 SOLARIS trial results

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new, “positive” data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine ...
Seeking Alpha

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults ...

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology ...
Nasdaq

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for ...

TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new ...
Eagle-Tribune

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results ...

Beyond the SOLARIS study, Teva presented results from in vitro studies that evaluated TEV-'749 against the currently marketed intramuscular olanzapine long-acting injectable for the risk of PDSS, as ...
Seeking Alpha

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV ...

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® ...